AIDS

[CytoDyn, Inc.] CytoDyn, Inc., a biotechnology company developing leronlimab, a CCR5 antagonist, announced its clinical trial with leronlimab in combination with carboplatin for the treatment of metastatic TNBC has advanced from Phase Ib to a Phase II trial.

[Nature Reviews Genetics] HIV host genomic research, which aims to understand how human genetic variation affects our response to HIV infection, has progressed from early candidate gene studies to recent multi-omic efforts, benefiting from spectacular advances in sequencing technology and data science.

[Nature Communications] Investigators reported that Vpr counteracts lysosomal-associated transmembrane protein 5 (LAPTM5), a potent inhibitor of HIV-1 particle infectivity, to enhance HIV-1 infection in macrophages.

[Microbiology and Molecular Biology Reviews] CD8+ T cell noncytotoxic antiviral responses have now been observed with other virus families but are mediated by different cytokines. Characterizing the protein structure of CAF has been challenging despite many biologic, immunologic, and molecular studies.

[Nature Communications] Scientists reported, using the pathogenic model of antiretroviral therapy-treated, SIV-infected rhesus macaques that sequential interleukin-21 and interferon alpha therapy generated terminally differentiated blood natural killer cells with potent human leukocyte antigen-E-restricted activity in response to SIV envelope peptides.

[Science Advances] The authors highlighted the unprecedented therapeutic potential of an implantable vascularized hydrogel with ovarian spheroids against menopause and suggested that it might be used as an alternative approach to standard hormone therapy.